- Home
- ALLR vs NCNA Comparison
ALLR vs NCNA Comparison
Compare ALLR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- NCNA
- Stock Information
- Founded
- ALLR 2004
- NCNA 1997
- Country
- ALLR United States
- NCNA United Kingdom
- Employees
- ALLR N/A
- NCNA N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- NCNA Health Care
- Exchange
- ALLR Nasdaq
- NCNA Nasdaq
- Market Cap
- ALLR 15.8M
- NCNA 15.4M
- IPO Year
- ALLR N/A
- NCNA 2017
- Fundamental
- Price
- ALLR $0.94
- NCNA $3.44
- Analyst Decision
- ALLR Strong Buy
- NCNA Buy
- Analyst Count
- ALLR 1
- NCNA 2
- Target Price
- ALLR $9.00
- NCNA $5,000.00
- AVG Volume (30 Days)
- ALLR 367.8K
- NCNA 733.3K
- Earning Date
- ALLR 08-15-2025
- NCNA 08-20-2025
- Dividend Yield
- ALLR N/A
- NCNA N/A
- EPS Growth
- ALLR N/A
- NCNA N/A
- EPS
- ALLR N/A
- NCNA N/A
- Revenue
- ALLR N/A
- NCNA N/A
- Revenue This Year
- ALLR N/A
- NCNA N/A
- Revenue Next Year
- ALLR N/A
- NCNA N/A
- P/E Ratio
- ALLR N/A
- NCNA N/A
- Revenue Growth
- ALLR N/A
- NCNA N/A
- 52 Week Low
- ALLR $0.61
- NCNA $3.05
- 52 Week High
- ALLR $6.00
- NCNA $1,856.00
- Technical
- Relative Strength Index (RSI)
- ALLR 47.03
- NCNA 30.79
- Support Level
- ALLR $0.85
- NCNA $3.05
- Resistance Level
- ALLR $1.01
- NCNA $3.78
- Average True Range (ATR)
- ALLR 0.05
- NCNA 0.82
- MACD
- ALLR -0.01
- NCNA 0.11
- Stochastic Oscillator
- ALLR 47.55
- NCNA 5.61
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.